Lindsay Rosenwald Biography | Life Facts Of Lindsay Rosenwald

OpusPoint Partners:
Investing in the Future ofHealthcare and Life Sciences

At OpusPoint Partners,we have a vision for an amazing future for the life science and healthcare industry. We believe in that vision so strongly that we are investingmoney and time to advance life sciences and biotechnology. We also believe in a strong, healthy future for human kind. With proper funding and research, we know that the quality of healthcare can be catapulted to a new and more effective level.

A Vision for the Future of Healthcare
With this vision in mind, Michael S. Weiss and Dr. LindsayRosenwald created OpusPoint Partners in 2009. These men have over 40 years of combined experience in the fields of healthcare, life sciences and biotechnology investing. Both are creative thinkers who have founded a number of biotech companies over the years.

Dr. Lindsay A. Rosenwaldhas most recently founded Cougar Biotechnology Inc.,which is a Los Angeles-based firm that focuses on the field of oncology. Cougar’s oncology portfolio includes some promising experimental drugs effective in treatingnumerousforms of cancer. One of those in particular has drawn the interests of researchers and investors. It has proven to work well at treating late-stage prostate cancer. Dr. Lindsay Rosenwald negotiated a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars in July of 2009.

Achieving the Objectives
The objective of Lindsay Rosenwald and OpusPoint Partners is twofold: to move forward withintegrity in achieving long-term goals and short-termgains, and to build solid relationships in both the world of investing and biotechnology.  By establishing strong relationships withother industry leaders who share similar values, they believe that these goals and objectives can be obtained without the sacrifice of their principles and standards.

For OpusPoint Partners, honest investing with full and open disclosure is more than just good business. This is a way of life.They currently work with a wide range of corporations to create a team approach to supporting emerging new businesses in an effort to reach critical goals.  Dr. Lindsay Rosenwald and OpusPoint Partners have made a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.These pioneers of research and investment believe in a better future for us all; a future where diseases are diagnosed and treated by more effective methods.
At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, believe in a world where people’s lives and health are greatly improved. They believe in creating a future where mankind achieves a much stronger quality of life. Through thisunique vision they are making a true difference in theirworld. In order to attain this dream of a better tomorrow for us all, their journey often involves providing advisory services to start-up businesses.  Sometimes it requires investing in publicly-traded companies.

Raising the Bar
Dr. Lindsay Rosenwald and OpusPoint Partners, is working to raise the bar for investors. Their efforts include advising emerging biotechnical research facilities. They believe that a strong moral compass along with sound business principles can significantly minimize risks and thereby maximize returns for investors and so far, this unique formula is proving to be successful.

For the past 17 years, Dr. Rosenwald has been a well-respected Wall Street biotechnology entrepreneur. His business ethics have not gone unnoticed. He has, in fact, been instrumental in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

An Innovative Business Philosophy
During his impressive twenty-year career, Dr. Lindsay Rosenwald has founded over fifty companies and managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. During the years of 2002 through 2006, he also managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

The philosophy behind OpusPoint Partners will be to build a successful life science and healthcare network that plays fair and does not take short cuts to reach its goals. Dr. Rosenwald and his associates know that the world we currently live in often provides too many opportunities for business leaders to use less than ethical tactics to try to manipulate outcomes of clinical trials and hence increase quarterly earnings.
OpusPoint Partners is a uniqueenterprise that continually reinforces its commitment to its employees and investors. Their promise is to deal fairly in all aspects of experimental drug trials. In the investigation and manufacture of experimental drugs, they are resolute about these vows.

The Benefits of Making the World a Better Place
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.

But revolutionizing these age-old medicaland healthcare techniques and procedures is no small task, nor is it for the faint of heart. In order to effect changes on such a grand scale requires commitment; it requires time and money.  It also involves a strong resolve to work hard within the ethical boundaries that other drug research companies may have discarded in favor of better profits.

Dr. Rosenwaldunderscoresthe fact that over the past few years, projected goals have already been surpassed. By applying best practices and processes, OpusPoint Partners moves ahead earning superior, risk-adjusted returns and helpingto finance and support more than 20 companies in the past two years alone.  This achievement is marked by a continuing commitment to the financial world and the world of drug research.

Credentials and Lifetime Achievements
Dr. LindsayRosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector.The future of OpusPoint Partners looks very promising with Dr. Rosenwald as its vanguard.

OpusPoint Partners is an innovative new company with a unique vision for the future of the life science and healthcare industry. That vision includes some cutting edge technologies but also some forward thinking business philosophies.

As with alllofty visionssuchas this, itwill take immense commitment from quality entrepreneurs to accomplish. Michael S. Weiss and Dr. Lindsay Rosenwald created OpusPoint Partners in 2009 with the idea of combining their 40 years of experience and business acumen working toward revolutionizing the fields of healthcare, life sciences and biotechnology investing. Both these men are well equipped to do this job and have already founded a number of biotech companies over the years.

With so much at stake, OpusPoint Partners along with Dr. Lindsay Rosenwald, is working toward making those leaps to advance and even transform the world of life sciences and biotechnology investing. Rosenwald, along with his team at OpusPoint, believe in a future where mankind significantly improves the quality of healthcare, as well as healthcare investing.

Advancements in the Future of Healthcare
Recently, Dr. Lindsay A. Rosenwaldfounded Cougar Biotechnology Inc. This Los Angeles-based company focuses on the field of oncology. Their oncology portfolio includes some very promising experimental drugs, which are proving to be effective in treatingnumerousforms of cancer.

One in particular has caused some excitement and drawn the interests of researchers and investors. It is a new drug that has been proven to work well at treating late-stage prostate cancer. In July of 2009, Dr. Lindsay Rosenwaldwas able to negotiate a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars.

Realizing the Objectives
Lindsay Rosenwald and OpusPoint Partners believe they can continue to move forward with projects like these that alter healthcare significantly and produce results for the greater good of mankind. They achieve these goals with integrity, building solid relationships in both the world of investing and biotechnology.

Establishing robust relationships withother industry leaders who share similar values is a hallmark of the business strategy of both Dr. Lindsay Rosenwald and OpusPoint Partners. They believe in reaching goals and objectives through honesty, integrity and hard work. Their success has proven that you can obtain these objectives without the sacrifice ofprinciples and standards. Honest investing with full and open disclosure is more than just good business for OpusPoint Partners. This is the ideology they live by.

Creating New Partnerships for a Better Tomorrow
Dr. Lindsay Rosenwald and OpusPoint Partners currently work with a wide range of businesses and organizations to create a team approach for thesupport of emerging new businesses. They are making great strides toward building a powerful network of like-minded individuals who all possess a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.

With pioneers such as these in the areas of research and investment, you can be sure that thefuture of healthcare and life sciences will continue to flourish. These days, the medical field is well-aware of its need for diseases of all types to be diagnosed and treated by more effective methods. At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, know that the dream can become a reality with hard work and dedication.

The dream of a better tomorrow continues to be the fuel that fires this vision of a much stronger quality of life for us all. And thisunique vision of making a true difference in the world has become a driving force for Dr. Lindsay Rosenwald and OpusPoint Partners. History shows that dreams like this always take time, money and hard work, plus dedication from those involved.

Raising the Bar for Investors
Over the course of this journey, Dr. Lindsay Rosenwald and OpusPoint Partners must oftenprovide advisory services to start-up businesses. At times they also must invest in publicly-traded companies in order to move the vision forward.

One of their key objectives is to raise the bar for all investors. Whether working in the advisory capacity with emerging biotechnical research facilities or actually investing, OpusPoint followsa strong moral compass.With sound business principleslike these, the risks can be significantly minimizedand the returns for investors maximized. This uniqueformula has proven successful beyond anyone’s wildest dreams.

Utilizing Ethical Business Practices
The philosophy behind OpusPoint Partners is to build a positive and effective life science and healthcare network that plays fair and won’t take short cuts to reach its goals. Dr. Rosenwaldknows from experience, that today’s world often provides many opportunities for business leaders to use less than ethical tactics to try and manipulate outcomes of clinical trials with an eye toward greaterquarterly earnings. Does the end justify the means?

At OpusPoint Partners, the answer is a resounding no! This unique enterprise continually reinforces its commitment to its employees and investors to conduct business with higher standards than many of days gone by. In the investigation and manufacture of experimental drugs, they are resolute about this commitment to honest, above-board business dealings.

A Long and Fruitful Career
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.

Dr. Rosenwald, a well-respected Wall Street biotechnology entrepreneur, has worked for the past 17 years utilizing strong business ethics in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

Throughout an impressive twenty-year career, Dr. Lindsay Rosenwald has established over fifty companies. He also managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. From 2002 to 2006, hemanaged the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

Dr. Lindsay Rosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector. The future ofOpusPoint Partners indeed looks promising with Dr. Rosenwald at its helm.

Based on the results observed in patients, who received abiraterone acetate plus prednisone/prednisolone, Johnson & Johnson plans to file marketing applications for a promising discovery, abiraterone acetate, which significantly increases overall survival in patients with advanced prostate cancer progressed after chemotherapy.

Randomized, placebo-controlled Phase III study, COU-AA-301, shows that patients receiving abiraterone plus low doses of prednisone live longer if compared to patients receiving placebo plus prednisone. The study involved 1195 patients with castration-resistant prostate cancer (CRPC) or metastatic advanced prostate cancer. The patients were previously treated with docetaxel-based chemotherapy and their disease progressed after the treatment leaving no choice.

The results of the study were shared at the Presidential Symposium at the 35th Annual European Society for Medical Oncology (ESMO) Congress. According to the data analysis, patients treated with abiraterone had 35 percent less risk of death and their median survival was 14.8 months compared with 10.9 months of the placebo group.

In addition, patients treated with abiraterone acetate plus a low dose of prednisone/prednisolone demonstrated great improvements in secondary study endpoints if compared with the placebo plus prednisone group: median time to PSA progression (TTPP) was 10.2 months for abiraterone acetate and only 6.6 months for placebo. Total PSA response was achieved in 38 % of patients receiving abiraterone vs 10 % in the placebo group.

Furthermore, patients in the abiraterone group had less toxic adverse effects if compared to chemotherapy. However they experienced more corticoid-related side effects than patients in the placebo group. Most frequently, they suffered fluid retention (30.5 % comparing with 22.3 % in the placebo group) and hypokalemia (17 % vs. 8.4 %). Liver function abnormalities were observed in 10 % of abiraterone treated patients compared to 8 % of placebo plus prednisone patients.

According to physicians and investors, like Johan S. de Bono, MD, and Lindsay Rosenwald, MD, abiraterone acetate has all the potential to meet the needs of late-stage prostate cancer patients. Because the drug can extend survival for men with castrate-resistant prostate cancer progressed after chemotherapy, the results are very promising.

As Lindsay Rosenwald says, prostate cancer is number 5 killer among all cancers and it is very important to invest in promising oncology candidates with a significant potential.

Howard I. Scher, MD, of Memorial Sloan-Kettering Cancer Center believes that abiraterone acetate is very promising for those patients who had very poor prognosis and little treatment options. The drug is an important step forward that may impact the lives of many patients.

Ortho Biotech Oncology Research & Development, an affiliate of Cougar Biotechnology, Inc. sponsored by Lindsay Rosenwald’s investment bank, previously announced that the Phase III study should be un-blinded after interim analysis showed a significant survival improvement in the abiraterone acetate group and the drug’s acceptable safety profile. Independent Data Monitoring Committee (IDMC) also recommended that men in the placebo group be offered abiraterone.

It was in the fall of 1995 when I answered the New York Time’s advertisement that stated that an up and coming venture capital firm was looking for a CEO to assist its specialty medical centers.

I was escorted into Dr. Lindsay Rosenwald’s office for the interview, where I then sat for about six hours, watching him take several phone calls simultaneously, assist endless rounds of visitors, effectively directing trades as he observed the market activity on one of four terminals set up for this purpose.  It was at the end of the day that he let me know I was hired and that the next morning I would be able to come back and discuss the details.

It was later that evening that I discussed the events of my day with my brother, Tom.  He was ecstatic, and declared “Do you have any idea who Lindsay Rosenwald is?!”  To say that this meeting with Dr Rosenwald changed my life would be an understatement.

Lindsay Rosenwald gave me a chance that few others would have given me.  My knowledge of the public markets was limited.  What I had to offer was an understanding of nutritional concepts.  Still, he took me under his wing and introduced me to venture capital, financing, public companies, and merchant banking.  The entire experience was intense, fascinating, exciting, and it changed my life.

I am eternally grateful for Lindsay’s assistance.  He was a teacher to me as well as a friend.  He taught me incredibly valuable lessons that I still cite on a regular basis today: pick a direction and stay focused; even though pioneers may get the arrows, the settlers get the land; it’s better to own a tenth of a gold mine than all of the shaft; and don’t worry about gossip – it’s just another form of praise.

Lindsay Rosenwald is a smart and relentless man who works hard.  He’s an easy man to admire for these traits alone, but more than these I admire his foresight and his ability to see potential in things.  This ranges from potential CEOs like me to companies to invest in and more.  He not only sees that potential but he helps to provide the environment where it can thrive and where people can truly reach their full potential.  Whether or not Dr. Rosenwald is ever given appropriate thanks, he has launched a multitude of successful careers.  Even if we all had talent, it was his nurturing and insight that allowed us to reach our potential.

Lindsay Rosenwald has been a helping hand to many.  Whether it’s his investment in companies financially, help directly in setup, assistance through advice, or the many public companies that he created which have since given countless additional opportunities.